world
AstraZeneca pays Dizal $600 million upfront for global rights to lung-cancer drug, with up to $900 million more in milestones
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to a lung cancer treatment. Dizal could receive another $900 million in milestone payments.
Jul 14, 2:59 AM·1m read2 sources
manilatimes.netAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
AstraZeneca entered an exclusive global license agreement with China’s Dizal Pharmaceutical for a lung cancer treatment, paying $600 million upfront with Dizal eligible for up to $900 million more in milestones. Dizal is eligible for up to $900 million in additional payments tied to clinical development and sales milestones.
The agreement was disclosed in a filing to the Shanghai stock exchange on July 14, 2026. @WSJ reported the deal centers on one of Dizal’s drugs for a type of lung cancer.
Transparency
How sources framed this
These outlets didn't split into competing frames — coverage was uniform.
CorroborationModerate · 2 sources
